Grade ≥ 3 AEs regardless of attribution to navoximod
| Navoximod 50 mg BID (n = 1) | Navoximod 100 mg BID (n = 3) | Navoximod 200 mg BID (n = 3) | Navoximod 400 mg BID (n = 3) | Navoximod 600 mg BID (n = 3) | Navoximod 800 mg BID (n = 6) | All Patients 21/28 day schedule (N = 19) | Navoximod continuous schedule 600 mg BID (n = 3) | All Patients (N = 22) | |
|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | 1 (100%) | 3 (100%) | 1 (33%) | 3 (100%) | 2 (67%) | 2 (33%) | 12 (63%) | 2 (67%) | 14 (63%) |
| Neoplasm progression | – | – | 1 (33%) | 1 (33%) | 1 (33%) | – | 3 (16%) | – | 3 (14%) |
| AST increased | – | – | 1 (33%) | 1 (33%) | – | 2 (11%) | – | 2 (9%) | |
| Anemia | – | – | – | – | 1 (33%) | – | 1 (5%) | – | 1 (5%) |
| Ascites | – | – | – | – | 1 (33%) | – | 1 (5%) | – | 1 (5%) |
| Dysphagia | 1 (33%) | – | – | – | – | 1 (5%) | – | 1 (5%) | |
| Hypokalemia | – | – | – | – | 1 (17%) | 1 (5%) | – | 1 (5%) | |
| Hypotension | – | – | – | – | 1 (17%) | 1 (5%) | – | 1 (5%) | |
| Lower GI hemorrhage | – | – | – | – | 1 (17%) | 1 (5%) | – | 1 (5%) | |
| Mental status changes | – | – | – | 1 (33%) | – | 1 (5%) | – | 1 (5%) | |
| Muscular weakness | – | – | – | – | 1 (33%) | – | 1 (5%) | – | 1 (5%) |
| Peripheral neuropathy | – | – | – | 1 (33%) | – | – | 1 (5%) | – | 1 (5%) |
| Acute pancreatitis | – | 1 (33%) | – | – | – | – | 1 (5%) | – | 1 (5%) |
| Pneumonia | – | 1 (33%) | – | – | – | – | 1 (5%) | – | 1 (5%) |
| Small Intestinal Obstruction | – | 1 (33%) | – | – | – | – | 1 (5%) | – | 1 (5%) |
| Tumor pain | – | – | – | – | 1 (33%) | – | 1 (5%) | – | 1 (5%) |
| Bloody discharge | – | – | – | – | – | – | – | 1 (33%) | 1 (5%) |
| Diverticulitis | – | – | – | – | – | – | – | 1 (33%) | 1 (5%) |
| Lymphopenia | – | – | – | – | – | – | – | 1 (33%) | 1 (5%) |